Larvol Delta - LowDensity-Lipoprotein-Cholesterol-Reduction-With-Alirocumab-150-mg-Versus-Inclisiran-in-Individuals-Initiating-Therapy-in-Routine-Clinical-Practice

Leqvio (inclisiran) - Novartis

Praluent (alirocumab) - Sanofi, Regeneron

http://clinicaltrials.gov/ct2/show/NCT07615166

May 30, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next